Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients

John Levenick, Stuart R. Gordon, Linda L. Fadden, L. Campbell Levy, Matthew J. Rockacy, Sarah M. Hyder, Brian E. Lacy, Steven P. Bensen, Douglas D. Parr, Timothy B. Gardner

Research output: Contribution to journalArticle

81 Scopus citations

Abstract

Background & Aims Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials. The European Society for Gastrointestinal Endoscopy guidelines recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including those at average risk for pancreatitis. We performed a randomized controlled trail to investigate the efficacy of this approach. Methods We performed a prospective, double-blind, placebo-controlled trial of 449 consecutive patients undergoing ERCP at Dartmouth Hitchcock Medical Center, from March 2013 through December 2014. Approximately 70% of the cohort were at average risk for PEP. Subjects were assigned randomly to groups given either a single 100-mg dose of rectal indomethacin (n = 223) or a placebo suppository (n = 226) during the procedure. The primary outcome was the development of post-ERCP pancreatitis (PEP), defined by new upper-abdominal pain, a lipase level more than 3-fold the upper limit of normal, and hospitalization after ERCP for 2 consecutive nights. Results There were no differences between the groups in baseline clinical or procedural characteristics. Sixteen patients in the indomethacin group (7.2%) and 11 in the placebo group (4.9%) developed PEP (P =.33). Complications and the severity of PEP were similar between groups. Per a priori protocol guidelines, the study was stopped owing to futility. Conclusions In a randomized controlled study of consecutive patients undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalGastroenterology
Volume150
Issue number4
DOIs
StatePublished - Apr 1 2016

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients'. Together they form a unique fingerprint.

  • Cite this

    Levenick, J., Gordon, S. R., Fadden, L. L., Campbell Levy, L., Rockacy, M. J., Hyder, S. M., Lacy, B. E., Bensen, S. P., Parr, D. D., & Gardner, T. B. (2016). Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. Gastroenterology, 150(4), 911-917. https://doi.org/10.1053/j.gastro.2015.12.040